Severity of coronary atherosclerosis in patients with COPD

Clinical Respiratory Journal

Volumn 11, Issue 6, 2017, Pages 751-756

  Dursunoglu, Neşe ^a   Dursunoglu, Dursun ^a   Yıldız, Ali İhsan ^a   Uludag, Burcu ^a   Alaçam, Zahide Namlı ^a   Sarıçopur, Ahmet ^a  

^a PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

chronic obstructive pulmonary disease GOLD grade FEV1 FVC coronary artery disease Gensini score

Indexed keywords

LIPID;

ADULT; AGE; AGED; ARTERY LESION; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GENSINI SCORE; GLOBAL INITIATIVE FOR OBSTRUCTIVE LUNG DISEASE GRADE; HUMAN; HYPERTENSION; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE ASSESSMENT; RISK FACTOR; SMOKING; CEREBROVASCULAR ACCIDENT; COMORBIDITY; COMPLICATION; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

AGED; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; STROKE;

EID: 84954289039     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12412     Document Type: Article

References (29)

1. GOLD Committee. Global Strategy for the Diagnosis Management and Prevention of COPD. New York, Global Initiative for Chronic Obstructive Lung Disease, 2014.
2. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823): 1341–51.
3. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest. 1998;113: 576–83.
4. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32: 962–9.
5. Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med. 2006;12: 106–12.
6. Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5: 543–8.
7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136: 225–44.
8. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51: 606.
9. Han MK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases and the heart. Circulation. 2007;116: 2992–3005.
10. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59: 574–80.
11. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101: 530–5.
12. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128: 2068–75.
13. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127: 1952–9.
14. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343: 1902–9.
15. Durand J, Leroy-Ladurie M, Ransom-Bitker B. Effects of hypoxia and hypercapnia on the repartition of pulmonary blood flow in supine subjects. Respir Res. 1970;5: 156–65.
16. Kiely DG, Cargill RI, Lipworth BJ. Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans. Chest. 1996;109: 1215–21.
17. Chabot F, Mertes PM, Delorme N, Schrijen FV, Saunier CG, Polu JM. Effect of acute hypercapnia on alpha atrial natriuretic peptide, renin, angiotensin II, aldosterone, and vasopressin plasma levels in patients with COPD. Chest. 1995;107: 780–6.
18. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004;110: 1747–53.
19. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2: 44–9.
20. Ashitani J, Mukae H, Arimura Y, Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002;41: 181–5.
21. Schroeder EB, Welch VL, Couper D, Nieto FJ, Liao D, Rosamond WD, Heiss G. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2003;158: 1171–81.
22. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med. 2005;99: 670–82.
23. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60: 925–31.
24. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364: 937–52.
25. Topsakal R, Kalay N, Ozdogru I, Cetinkaya Y, Oymak S, Kaya MG, Dogan A, Inanc MT, Ergin A. Effects of chronic obstructive pulmonary disease on coronary atherosclerosis. Heart Vessels. 2009;24(3): 164–8.
26. Divo M, Cote C, de Torres J, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2): 155–61.
27. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9): 1376–84.
28. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142: 233–9.
29. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93: 391–8.